Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Yalan Lu, Deqiang Han, Wenjie Liu, Rong Huang, Jinhuan Ou, Xiaoqiao Chen, Xizhe Zhang, Xuezhi Wang, Shijun Li, Lin Wang, Changzheng Liu, Shiying Miao, Linfang Wang, Changwu Ma & Wei Song. (2018) RNF138 confers cisplatin resistance in gastric cancer cells via activating Chk1 signaling pathway. Cancer Biology & Therapy 19:12, pages 1128-1138.
Read now
Read now
Piaopiao Jin, Chi Chun Wong, Sibin Mei, Xingkang He, Yun Qian & Leimin Sun. (2016) MK-2206 co-treatment with 5-fluorouracil or doxorubicin enhances chemosensitivity and apoptosis in gastric cancer by attenuation of Akt phosphorylation. OncoTargets and Therapy 9, pages 4387-4396.
Read now
Read now
Articles from other publishers (23)
Marina Ferreira Candido, Mariana Medeiros, Luciana Chain Veronez, David Bastos, Karla Laissa Oliveira, Julia Alejandra Pezuk, Elvis Terci Valera & María Sol Brassesco. (2023) Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario. Pharmaceutics 15:2, pages 664.
Crossref
Crossref
Forough Alemi, Faezeh Malakoti, Mostafa Vaghari‐Tabari, Jafar Soleimanpour, Nazila Shabestani, Aydin R. Sadigh, Nafiseh Khelghati, Zatollah Asemi, Yasin Ahmadi & Bahman Yousefi. (2022) DNA damage response signaling pathways as important targets for combination therapy and chemotherapy sensitization in osteosarcoma. Journal of Cellular Physiology 237:5, pages 2374-2386.
Crossref
Crossref
Bo Wu, Wenzhuo Yang, Zhaoyu Fu, Haoqun Xie, Zhen Guo, Daqun Liu, Junliang Ge, Sheng Zhong, Luwei Liu, Jingyi Liu & Dong Zhu. (2021) Selected using bioinformatics and molecular docking analyses, PHA-793887 is effective against osteosarcoma. Aging.
Crossref
Crossref
Fatemeh Sadoughi, Parisa Maleki Dana, Zatollah Asemi & Bahman Yousefi. (2021) DNA damage response and repair in osteosarcoma: Defects, regulation and therapeutic implications. DNA Repair 102, pages 103105.
Crossref
Crossref
Biyu Zhang, Lei Yang, Xin Wang & Denggang Fu. (2021) Identification of a survival-related signature for sarcoma patients through integrated transcriptomic and proteomic profiling analyses. Gene 764, pages 145105.
Crossref
Crossref
Andrea Ghelli Luserna di Rorà, Claudio Cerchione, Giovanni Martinelli & Giorgia Simonetti. (2020) A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target. Journal of Hematology & Oncology 13:1.
Crossref
Crossref
Weixu Li, Yan Li, Wenjia Tian, Xiuguo Han, Jie Zhao, Zengfeng Xin, Hejia Hu, Jun Li, Kai Hang & Rongzhen Xu. (2020) 2-methylbenzoyl berbamine, a multi-targeted inhibitor, suppresses the growth of human osteosarcoma through disabling NF-κB, ERK and AKT signaling networks. Aging 12:14, pages 15037-15049.
Crossref
Crossref
Nne E. Uko, Osman F. Güner, Diane F. Matesic & J. Phillip Bowen. (2020) Akt Pathway Inhibitors. Current Topics in Medicinal Chemistry 20:10, pages 883-900.
Crossref
Crossref
Jian Zhu, Hanhui Zou, Wei Yu, Yuluan Huang, Bing Liu, Tao Li, Chengzhen Liang & Huimin Tao. (2019) Checkpoint kinase inhibitor AZD7762 enhance cisplatin-induced apoptosis in osteosarcoma cells. Cancer Cell International 19:1.
Crossref
Crossref
Marwan Kwok & Tatjana Stankovic. 2019. Targeting Cell Survival Pathways to Enhance Response to Chemotherapy. Targeting Cell Survival Pathways to Enhance Response to Chemotherapy
203
230
.
Shu‐Yuan Cheng, Anayatzinc Vargas, Ji‐Young Lee, Cristina C. Clement & Elise Champeil. (2018)
Involvement of Akt in mitomycin C and its analog triggered cytotoxicity in
MCF
‐7 and K562 cancer cells
. Chemical Biology & Drug Design 92:6, pages 2022-2034.
Crossref
Crossref
Xueyan Hou, Hao Luo, Mengqi Zhang, Guoyi Yan, Chunlan Pu, Suke Lan & Rui Li. (2018)
Synthesis and biological evaluation of 3-(1,3,4-oxadiazol-2-yl)-1,8-naphthyridin-4(1
H
)-ones as cisplatin sensitizers
. MedChemComm 9:11, pages 1949-1960.
Crossref
Crossref
Zejun Fang, Chaoju Gong, Songshan Yu, Weihua Zhou, Waseem Hassan, Hongzhang Li, Xue Wang, Yanyan Hu, Kaipeng Gu, Xixi Chen, Bing Hong, Yuyan Bao, Xiang Chen, Xiaomin Zhang & Hong Liu. (2018) NFYB-induced high expression of E2F1 contributes to oxaliplatin resistance in colorectal cancer via the enhancement of CHK1 signaling. Cancer Letters 415, pages 58-72.
Crossref
Crossref
Ravi S. Narayan, Carlos A. Fedrigo, Eelke Brands, Rogier Dik, Lukas J.A. Stalpers, Brigitta G. Baumert, Ben J. Slotman, Bart A. Westerman, Godefridus J. Peters & Peter Sminia. (2017) The allosteric AKT inhibitor MK2206 shows a synergistic interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures. BMC Cancer 17:1.
Crossref
Crossref
Jarmila Herůdková, Kamil Paruch, Prashant Khirsariya, Karel Souček, Martin Krkoška, Olga Vondálová Blanářová, Petr Sova, Alois Kozubík & Alena Hyršlová Vaculová. (2017) Chk1 Inhibitor SCH900776 Effectively Potentiates the Cytotoxic Effects of Platinum-Based Chemotherapeutic Drugs in Human Colon Cancer Cells. Neoplasia 19:10, pages 830-841.
Crossref
Crossref
Toshihiro Matsuo, Keiji Sato, Takuya Matsui, Shigeyuki Sawada, Yoshitaka Muramatsu, Katsuhisa Kawanami & Masataka Deie. (2017) Inhibitory effects of low-intensity pulsed ultrasound sonication on the proliferation of osteosarcoma cells. Oncology Letters 14:3, pages 3071-3076.
Crossref
Crossref
Synnøve Yndestad, Eilin Austreid, Ida R. Svanberg, Stian Knappskog, Per E. Lønning & Hans P. Eikesdal. (2017) Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines. Oncotarget 8:25, pages 41227-41241.
Crossref
Crossref
Yu Guo, Ya-Hong Chen, Zhi-Hua Cheng, Huo-Niu Ou-Yang, Cong Luo & Zhi-Lin Guo. (2016) Tectorigenin inhibits osteosarcoma cell migration through downregulation of matrix metalloproteinases in vitro. Anti-Cancer Drugs 27:6, pages 540-546.
Crossref
Crossref
Xiu-guo Han, Yan Li, Hui-min Mo, Kang Li, Du Lin, Chang-qing Zhao, Jie Zhao & Ting-ting Tang. (2016) TIMP3 regulates osteosarcoma cell migration, invasion, and chemotherapeutic resistances. Tumor Biology 37:7, pages 8857-8867.
Crossref
Crossref
Batzaya Davaadelger, Lei Duan, Ricardo E. Perez, Steven Gitelis & Carl G. Maki. (2016) Crosstalk between the IGF-1R/AKT/mTORC1 pathway and the tumor suppressors p53 and p27 determines cisplatin sensitivity and limits the effectiveness of an IGF-1R pathway inhibitor. Oncotarget 7:19, pages 27511-27526.
Crossref
Crossref
Kaixiong Tao, Yuping Yin, Qian Shen, Ying Chen, Ruidong Li, Weilong Chang, Jie Bai, Weizhen Liu, Liang Shi & Peng Zhang. (2016) Akt inhibitor MK-2206 enhances the effect of cisplatin in gastric cancer cells. Biomedical Reports.
Crossref
Crossref
Hua Chen, Jacson Shen, Edwin Choy, Francis J. Hornicek & Zhenfeng Duan. (2016) Targeting protein kinases to reverse multidrug resistance in sarcoma. Cancer Treatment Reviews 43, pages 8-18.
Crossref
Crossref
Xiu-guo Han, Lin Du, Han Qiao, Bing Tu, Yu-gang Wang, An Qin, Ke-rong Dai, Qi-ming Fan & Ting-ting Tang. (2015) CXCR1 knockdown improves the sensitivity of osteosarcoma to cisplatin. Cancer Letters 369:2, pages 405-415.
Crossref
Crossref